SCHEMBL4497151

SCHEMBL4497151

O=C(Nc1ccc(N2CCOCC2)cc1)c1nnc(NC(=O)c2cccc3ccccc23)o1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 9/20 0.71
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
MAPT P10636 4/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
HCRTR1 O43613 1/20 0.53
KDM4E B2RXH2 3/20 0.53
LMNA P02545 2/20 0.51
POLB P06746 2/20 0.51
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 1/20 0.51
TP53 P04637 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HSD17B10 Q99714 1/20 0.51
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3547422 0.86 DGAT1 (0.75) DGAT1MEN1KMT2AMAPTKDM4E
SCHEMBL4506702 0.83 DGAT1 (1.00) DGAT1MEN1KMT2AMAPTLMNA
SCHEMBL4511242 0.82 DGAT1 (0.78) DGAT1MEN1KMT2AMAPTHCRTR1
SCHEMBL3542205 0.80 DGAT1 (1.00) DGAT1
SCHEMBL3544122 0.80 DGAT1 (0.79) DGAT1MEN1KMT2AMAPTKDM4E
SCHEMBL4514626 0.78 DGAT1 (0.78) DGAT1MEN1KMT2AMAPTNPC1
SCHEMBL4517196 0.78 DGAT1 (0.78) DGAT1MEN1KMT2AMAPTKDM4E
SCHEMBL3546009 0.78 DGAT1 (0.75) DGAT1KMT2AMAPTPOLBNPC1
SCHEMBL4497936 0.78 DGAT1 (0.74) DGAT1MEN1KMT2AMAPTKDM4E
SCHEMBL4501744 0.78 DGAT1 (0.81) DGAT1MEN1KMT2AMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US claimed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP claimed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO claimed
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP disclosed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT2, GPR119, DGAT1 DGAT1 3/4885MEN1 3117/4885KMT2A 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.